Across
- 2. phrase relating to DAA coverage of all genotypes
- 4. DAAs are contraindicated with these CYP strong inducers
- 6. scarring of the liver
- 9. first line treatment class of HCV
- 12. use of this drug class with Epclusa is not recommended
- 13. lab that is required throughout course of therapy dependent on patient risk factors
- 15. black box warning of DAAs
- 16. lab that is drawn 12 weeks after therapy completion
- 17. brand name of glecaprevir/pibrentasvir
Down
- 1. previous treatment option for HCV that has fallen out of favor
- 3. DAA mechanism class that must be taken with food
- 5. inflammation of the liver
- 7. transmission of HCV
- 8. combination with this drug class can increase risk of myopathy
- 10. sofosbuvir mechanism of action
- 11. treatment duration of Epclusa
- 14. common side effect of DAAs
- 15. type of hepatitis that does not have vaccine coverage